Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Omega-3 fatty acid and vitamin d levels to identify and attenuate cognitive aging in individuals

A vitamin, fatty acid technology, applied in the active agent of slowing or preventing cognitive decline, identifying the field of cognitive decline tendency of individuals

Pending Publication Date: 2019-10-25
SOC DES PROD NESTLE SA
View PDF10 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] Several short-term studies also failed to show the effect of the combination of B6, B12, and folic acid on improving cognitive function

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Omega-3 fatty acid and vitamin d levels to identify and attenuate cognitive aging in individuals
  • Omega-3 fatty acid and vitamin d levels to identify and attenuate cognitive aging in individuals
  • Omega-3 fatty acid and vitamin d levels to identify and attenuate cognitive aging in individuals

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0239] The Multidomain Alzheimer's Prevention Trial (MAPT) was designed to evaluate the efficacy of the following compared with placebo in reducing the rate of cognitive decline in adults 70 years of age or older: omega-3 supplementation ( DHA800mg per day, EPA 200), multi-domain intervention (nutritional counseling, physical exercise, cognitive stimulation) or a combination of supplements + multi-domain. Post hoc analyzes of MAPT results indicated that ω3 supplementation prevented cognitive decline in individuals with lower ω3 status at baseline. The VITACOG trial showed that homocysteine-lowering B vitamins reduced overall brain atrophy in individuals aged 70 years and older with MCI and hyperhomocysteinemia. Two consecutive post hoc reports by VITACOG showed that the effects of B vitamins on overall brain atrophy and cognitive decline were most pronounced in individuals in the highest tertile of baseline omega 3 status. Baseline nutritional status and nutrient interactions...

Embodiment 2

[0267] The following non-limiting examples are illustrative of compositions of embodiments provided by the present disclosure for reducing cognitive aging in non-demented individuals.

[0268] Element dose / day DHA 770mg EPA 700mg Vitamin B1 (thiamine) 50mg Vitamin B2 (riboflavin) 15mg Vitamin B3 (niacin) 25mg Vitamin B5 (pantothenic acid) 23mg Vitamin B6 (pyridoxine) 18mg Vitamin B7 (Biotin) 0.15mg Vitamin B9 (anhydrous folic acid) 0.4mg Vitamin B12 (cobalamin) About 12 to 21 times the RDA of vitamin B12 Vitamin C 500mg Vitamin D 0.015mg Vitamin E 82.6mg selenium 0.08mg Citrulline 3000mg Choline bitartrate 85mg

[0269] The following numbered paragraphs further describe the invention:

[0270] 1. A method of reducing, treating or preventing cognitive aging in a non-demented individual in need thereof or at risk, the method comprising administering to t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A method for identifying pre-disposition to cognitive decline in a subject, the method comprising determining levels of: (a) omega-3 fatty acids, and vitamin D or a metabolite thereof; (b) omega-3 fatty acids, and homocysteine; (c) vitamin D or a metabolite thereof, and homocysteine; or (d) omega-3 fatty acids, vitamin D or a metabolite thereof, and homocysteine, independently in one or more samples obtained from the subject.

Description

technical field [0001] The present invention relates to methods for identifying a predisposition to cognitive decline in an individual, and agents for slowing or preventing cognitive decline, in particular slowing or preventing cognitive decline in an individual identified according to the method of the invention. Background technique [0002] Population aging has always been a notable demographic event. The growth of the middle-aged and elderly population has outpaced the overall population growth due to increased lifespan, and the proportion of middle-aged and elderly people relative to the rest of the population has greatly increased due to the reduced birth rate. For example, in 1950, one in twelve individuals was at least 60 years old, and at the end of 2000, one in ten individuals was 60 or older. By the end of 2050, the number of people in the world aged 60 or over is projected to be one in five people. [0003] Aging individuals often suffer from some degree of cog...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/202A61P25/28A61K31/14A61K31/4415A61K31/51A61K31/592A61K31/593
CPCA61K31/14A61K31/202A61K31/4415A61K31/51A61K31/592A61K31/593A61K31/198A61K31/714A61P25/28A61K2300/00G01N33/6896G01N33/82G01N2800/2821
Inventor G·鲍曼J·L·于德里-拉贝J·A·J·施密特C·波沙
Owner SOC DES PROD NESTLE SA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products